| WordPress Gets AI Assistant That Can Edit Text, Generate Images and Tweak Your Site Feb 18th 2026, 16:00 by msmash WordPress has started rolling out an AI assistant built into its site editor and media library that can edit and translate text, generate and edit images through Google's Nano Banana model, and make structural changes to sites like creating new pages or swapping fonts. Users can also invoke the assistant by tagging "@ai" in block notes, a commenting feature added to the site editor in December's WordPress 6.9 update. The tool is opt-in -- users need to toggle on "AI tools" in their site settings -- though sites originally created using WordPress's AI website builder, launched last year, will have it enabled by default. Read more of this story at Slashdot. | | Lab-Grown Meat Exists (But Nobody Wants To Eat It) Feb 18th 2026, 15:20 by msmash An anonymous reader shares a report: In 2013, scientists unveiled the first lab-grown burger at a cost of $330,000. By 2023, the FDA approved cultivated chicken for sale. The price had dropped to around $10-$30 per pound, and over $3 billion in investor money had poured into more than 175 companies developing meat grown from animal cells instead of slaughtered animals. The promise is straightforward: real meat, no slaughter required. You could eat beef without killing cattle, chicken without industrial farming, steak without ethical compromise. The technology works. Federal regulators approved it as safe. And nearly a third of US states have banned it or are trying to. Not because it's dangerous -- because it threatens something deeper than food safety. Start with a small sample of animal cells -- a biopsy, not a slaughter. Place them in a bioreactor with nutrients. The cells multiply, forming muscle tissue identical to conventional meat at the cellular level. Nutritionally comparable, same protein content, but grown without raising and killing an animal. The process uses 64-90% less land than conventional meat production and drastically reduces greenhouse gas emissions. No factory farms, no slaughterhouses, no ethical compromise for people who love meat but hate industrial animal agriculture. For vegetarians who gave up meat for ethical reasons, it offers something impossible before: guilt-free steak. [...] Here's where the dream hits reality. Consumer surveys show people perceive conventional meat as tastier and healthier than lab-grown alternatives. Fewer consumers are willing to try cultivated options than expected. The words "lab-grown" and "cultivated" don't exactly make mouths water. Something about meat grown in a bioreactor triggers deep discomfort for many people, even those who claim to care about animal welfare and environmental impact. It's the same psychological barrier that made "Frankenfood" stick as a label for GMOs. Meat is supposed to come from animals, raised on farms, connected to land and tradition. Growing it in a facility feels wrong to people in ways they struggle to articulate.   Read more of this story at Slashdot. | | FDA Reverses Decision and Agrees To Review Moderna's Flu Vaccine Feb 18th 2026, 14:40 by msmash The Food and Drug Administration has reversed its decision on Moderna's flu vaccine and has agreed to review it for possible approval, Moderna announced on Wednesday. From a report: Last week, the agency rejected Moderna's application for review of a new flu vaccine, saying the company's research design was flawed. But in subsequent discussions the company said that the agency had relented and agreed to begin a review. Moderna said it split its application for the flu vaccine based on age, seeking a traditional approval for people 50 to 64 years old, and accelerated approval for those 65 and older. The company also said it agreed to conduct an additional study among those 65 and older once the vaccine reached the market. Moderna said on Wednesday that the F.D.A. set a deadline of August to decide whether to approve the vaccine. If it is authorized, it would be available for those older adults in the flu season that begins later this year. The vaccine uses messenger RNA technology, which Health Secretary Robert F. Kennedy Jr. has repeatedly criticized as unsafe and ineffective. The mRNA approach, which instructs the body to produce a fragment of a virus that sets off an immune response, was widely successful in Covid vaccines and is considered generally safe by public health experts and scientists. Read more of this story at Slashdot. | | India Tells University To Leave AI Summit After Presenting Chinese Robot as Its Own Feb 18th 2026, 14:00 by msmash An anonymous reader shares a report: An Indian university has been asked to vacate its stall at the country's flagship AI summit after a staff member was caught presenting a commercially available robotic dog made in China as its own creation, two government sources said. "You need to meet Orion. This has been developed by the Centre of Excellence at Galgotias University," Neha Singh, a professor of communications, told state-run broadcaster DD News this week in remarks that have since gone viral. But social media users quickly identified the robot as the Unitree Go2, sold by China's Unitree Robotics for about $2,800 and widely used in research and education globally. The episode has drawn sharp criticism and has cast an uncomfortable spotlight on India's artificial intelligence ambitions. Read more of this story at Slashdot. | | Thousands of CEOs Just Admitted AI Had No Impact On Employment Or Productivity Feb 18th 2026, 13:00 by BeauHD An anonymous reader quotes a report from Fortune: In 1987, economist and Nobel laureate Robert Solow made a stark observation about the stalling evolution of the Information Age: Following the advent of transistors, microprocessors, integrated circuits, and memory chips of the 1960s, economists and companies expected these new technologies to disrupt workplaces and result in a surge of productivity. Instead, productivity growth slowed, dropping from 2.9% from 1948 to 1973, to 1.1% after 1973. Newfangled computers were actually at times producing too much information, generating agonizingly detailed reports and printing them on reams of paper. What had promised to be a boom to workplace productivity was for several years a bust. This unexpected outcome became known as Solow's productivity paradox, thanks to the economist's observation of the phenomenon. "You can see the computer age everywhere but in the productivity statistics," Solow wrote in a New York Times Book Review article in 1987. New data on how C-suite executives are -- or aren't -- using AI shows history is repeating itself, complicating the similar promises economists and Big Tech founders made about the technology's impact on the workplace and economy. Despite 374 companies in the S&P 500 mentioning AI in earnings calls -- most of which said the technology's implementation in the firm was entirely positive -- according to a Financial Times analysis from September 2024 to 2025, those positive adoptions aren't being reflected in broader productivity gains. A study published this month by the National Bureau of Economic Research found that among 6,000 CEOs, chief financial officers, and other executives from firms who responded to various business outlook surveys in the U.S., U.K., Germany, and Australia, the vast majority see little impact from AI on their operations. While about two-thirds of executives reported using AI, that usage amounted to only about 1.5 hours per week, and 25% of respondents reported not using AI in the workplace at all. Nearly 90% of firms said AI has had no impact on employment or productivity over the last three years, the research noted. However, firms' expectations of AI's workplace and economic impact remained substantial: Executives also forecast AI will increase productivity by 1.4% and increase output by 0.8% over the next three years. While firms expected a 0.7% cut to employment over this time period, individual employees surveyed saw a 0.5% increase in employment. Read more of this story at Slashdot. | | Single Dose of DMT Rapidly Reduces Symptoms of Major Depression Feb 18th 2026, 10:00 by BeauHD In a small double-blind clinical trial, a single intravenous dose of DMT produced rapid and clinically meaningful reductions in symptoms of major depressive disorder within a week, with effects lasting up to three months in some patients. "Unlike psilocybin and lysergic acid diethylamide ( LSD), whose effects can last for hours, intravenous DMT has a half-life of around five minutes," notes ScienceAlert. "Its psychedelic effects are correspondingly brief, potentially making it more practical to administer in clinical settings." From the report: "A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to three months," writes a team led by neuroscientists David Erritzoe and Tommaso Barba of Imperial College London. [...] They recruited 34 participants with major depression and divided them into two groups of 17 for a double-blind, placebo-controlled trial. In the first stage of the trial, one group received an intravenous dose of DMT, while the other received an active placebo. Neither the researchers nor the participants were informed which participants received the DMT. The doses took around 10 minutes to administer, and a therapist sat with each participant to ensure comfort and safety while the psychedelic effects were active, remaining silent throughout the treatment. The treatment was generally well tolerated. Most side effects were mild to moderate, and included nausea, temporary anxiety, and pain at the injection site. No serious adverse events related to the treatment were reported, although brief increases in heart rate and blood pressure were observed immediately after dosing. In the second, open-label stage, two weeks after the first dose, all participants were given the opportunity to receive a dose of DMT. Participants were assessed before and at intervals after each dose using the Montgomery-Asberg Depression Rating Scale. Just a week after the first dose, participants who had received DMT had improved scores compared to the placebo group, and improvements were sustained during follow-up assessments. Two weeks after the first dose, the participants who received DMT scored about seven points lower, on average, than those who received a placebo. On this commonly used clinical scale, a drop of that size is generally considered a meaningful reduction in symptom severity. There was no significant difference between patients who received one or two doses of DMT, suggesting a single dose may be sufficient. These effects persisted for up to three months, and some patients remained in remission for at least six months following the treatment. The findings have been published in Nature Medicine. Read more of this story at Slashdot. | | Air Pollution Emerges As a Direct Risk Factor For Alzheimer's Disease Feb 18th 2026, 07:00 by BeauHD Longtime Slashdot reader walterbyrd shares a report from ABC News: In a study of nearly 28 million older Americans, long-term exposure to fine particle air pollution raised the risk of Alzheimer's disease. That link held even after researchers accounted for common conditions like high blood pressure, stroke and depression. Fine particle air pollution, known as PM2.5, consists of tiny particles in the air that come from car exhaust, power plants, wildfires, and burning fuels, according to the American Lung Association. They are small enough to travel deep into the lungs and even reach the bloodstream. The research, conducted at Emory University and published in PLOS Medicine, tracked health data over nearly two decades to explore whether air pollution harms the brain indirectly by causing high blood pressure or heart disease, which, in turn, leads to dementia. However, these "middleman" conditions accounted for less than 5% of the connection between pollution and Alzheimer's, the research found. The researchers say this suggests that over 95% of the Alzheimer's risk comes from the direct impact of breathing in dirty air, likely through inflammation or damage to brain cells. "The relationship between PM2.5 and AD [Alzheimer's disease] has been shown to be pretty much linear," said Kyle Steenland, a professor in the departments of environmental health and epidemiology at the Rollins School of Public Health at Emory University, and senior author of the study. "The reason this is particularly important is that PM2.5 is known to be associated with high blood pressure, stroke and depression -- all of which are associated with AD. So, from a prevention standpoint, simply treating these diseases will not get rid of the problem. We have to address exposure to PM2.5." Read more of this story at Slashdot. | |
Comments
Post a Comment